Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Freiburg CNS Non-Hodgkin Lymphoma Study
2005-000615-99Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, cytarabine, thiotepa, carmustine and dexamethasone in primary central nervous system lymphoma (PCNSL) and non-Hodgkin lymphoma (NHL), sponsored by University Hospital Freiburg. Primary endpoint: Complete response rate at 30 days after completion of blood stem-cell transplantation. Started Oct 2006; status: completed.
02
Drugs
methotrexatecytarabinethiotepacarmustinedexamethasone
03
Conditions
primary central nervous system lymphoma (PCNSL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2005-000615-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000615-99.